Literature DB >> 26102433

IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS.

Cynthia A Toth1, Francis Char Decroos, Gui-Shuang Ying, Sandra S Stinnett, Cynthia S Heydary, Russell Burns, Maureen Maguire, Daniel Martin, Glenn J Jaffe.   

Abstract

PURPOSE: To examine treatment decisions by ophthalmologists versus reading center fluid identification from optical coherence tomography in Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
METHODS: Fluid in 6,210 optical coherence tomography scans (598 patients) in "as needed treatment" arm of CATT Year 1 was compared with ophthalmologist's treatment: positive fluid agreement (PFA, fluid+, treatment+) and positive fluid discrepancy (PFD, fluid+, treatment-), negative fluid agreement (fluid-, treatment-) and negative fluid discrepancy (fluid-, treatment+). For PFDs, fluid location and visual acuity were characterized.
RESULTS: Treatment and reading center fluid determination agreed in 72.1% (53.0% PFA, 19.1% negative fluid agreement) and disagreed in 27.9% (25.7% PFD, 2.2% negative fluid discrepancy) of visits, with no discrepancies for 20.9% of patients. Compared with PFA, PFD occurred more commonly with lower total foveal thickness (mean ± SD: 265 ± 103 PFD, 366 ± 151 μm PFA), presence of intraretinal fluid only, smaller fluid areas (PFA areas greater than twice those of PFD, P < 0.001), and greater decrease in retinal and lesion thickness. Mean acuities before, at, and after PFD were 65.8, 66.9, and 66.3 letters.
CONCLUSION: Treatment decisions by ophthalmologists matched reading center fluid determination in the majority of visits. More pronounced response to treatment and smaller foci of fluid likely contributed to PFD. Positive fluid discrepancy did not have substantial impact on subsequent visual acuity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26102433      PMCID: PMC4479420          DOI: 10.1097/IAE.0000000000000483

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  20 in total

1.  Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).

Authors:  Lihteh Wu; María A Martínez-Castellanos; Hugo Quiroz-Mercado; J Fernando Arevalo; María H Berrocal; Michel E Farah; Mauricio Maia; José A Roca; Francisco J Rodriguez
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

2.  Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.

Authors:  Hajir Dadgostar; Alexandre A C M Ventura; Jeffrey Y Chung; Sumit Sharma; Peter K Kaiser
Journal:  Ophthalmology       Date:  2009-07-29       Impact factor: 12.079

3.  A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact.

Authors:  Omesh P Gupta; Gary Shienbaum; Avni H Patel; Christopher Fecarotta; Richard S Kaiser; Carl D Regillo
Journal:  Ophthalmology       Date:  2010-07-01       Impact factor: 12.079

4.  Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients.

Authors:  Waheeda Rahman; Fred Kuanfu Chen; Jonathan Yeoh; Lyndon da Cruz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-11-17       Impact factor: 3.117

5.  Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.

Authors:  Frank G Holz; Winfried Amoaku; Juan Donate; Robyn H Guymer; Ulrich Kellner; Reinier O Schlingemann; Andreas Weichselberger; Giovanni Staurenghi
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

6.  An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.

Authors:  Anne E Fung; Geeta A Lalwani; Philip J Rosenfeld; Sander R Dubovy; Stephan Michels; William J Feuer; Carmen A Puliafito; Janet L Davis; Harry W Flynn; Maria Esquiabro
Journal:  Am J Ophthalmol       Date:  2007-04       Impact factor: 5.258

7.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

8.  Comparison of spectral-domain versus time-domain optical coherence tomography in management of age-related macular degeneration with ranibizumab.

Authors:  Kaori Sayanagi; Sumit Sharma; Takuhiro Yamamoto; Peter K Kaiser
Journal:  Ophthalmology       Date:  2009-02-20       Impact factor: 12.079

9.  Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.

Authors:  Gui-shuang Ying; Jiayan Huang; Maureen G Maguire; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Ebenezer Daniel; Michael Klein; Dante Pieramici; John Wells; Daniel F Martin
Journal:  Ophthalmology       Date:  2012-10-06       Impact factor: 12.079

10.  A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.

Authors:  Geeta A Lalwani; Philip J Rosenfeld; Anne E Fung; Sander R Dubovy; Stephen Michels; William Feuer; Janet L Davis; Harry W Flynn; Maria Esquiabro
Journal:  Am J Ophthalmol       Date:  2009-04-18       Impact factor: 5.258

View more
  15 in total

1.  Deep learning-based automated detection of retinal diseases using optical coherence tomography images.

Authors:  Feng Li; Hua Chen; Zheng Liu; Xue-Dian Zhang; Min-Shan Jiang; Zhi-Zheng Wu; Kai-Qian Zhou
Journal:  Biomed Opt Express       Date:  2019-11-11       Impact factor: 3.732

2.  Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial.

Authors:  Drew Scoles; Gui-Shuang Ying; Wei Pan; Peiying Hua; Juan E Grunwald; Ebenezer Daniel; Glenn J Jaffe; Cynthia A Toth; Daniel F Martin; Maureen G Maguire
Journal:  JAMA Ophthalmol       Date:  2020-03-01       Impact factor: 7.389

3.  Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD)-a phase III, prospective, multicentre, randomized study: design and methods.

Authors:  Leonard M Coulibaly; Stefan Sacu; Philipp Fuchs; Hrvoje Bogunovic; Georg Faustmann; Christian Unterrainer; Gregor S Reiter; Ursula Schmidt-Erfurth
Journal:  Eye (Lond)       Date:  2022-07-05       Impact factor: 4.456

4.  Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.

Authors:  Nikhil S Patil; Andrew Mihalache; Arjan S Dhoot; Marko M Popovic; Rajeev H Muni; Peter J Kertes
Journal:  JAMA Ophthalmol       Date:  2022-06-01       Impact factor: 8.253

5.  Automated Quantitative Assessment of Retinal Fluid Volumes as Important Biomarkers in Neovascular Age-Related Macular Degeneration.

Authors:  Tiarnan D L Keenan; Usha Chakravarthy; Anat Loewenstein; Emily Y Chew; Ursula Schmidt-Erfurth
Journal:  Am J Ophthalmol       Date:  2021-02-15       Impact factor: 5.258

6.  Reliability of Retinal Pathology Quantification in Age-Related Macular Degeneration: Implications for Clinical Trials and Machine Learning Applications.

Authors:  Philipp L Müller; Bart Liefers; Tim Treis; Filipa Gomes Rodrigues; Abraham Olvera-Barrios; Bobby Paul; Narendra Dhingra; Andrew Lotery; Clare Bailey; Paul Taylor; Clarisa I Sánchez; Adnan Tufail
Journal:  Transl Vis Sci Technol       Date:  2021-03-01       Impact factor: 3.283

7.  Predicting wet age-related macular degeneration (AMD) using DARC (detecting apoptosing retinal cells) AI (artificial intelligence) technology.

Authors:  Paolo Corazza; John Maddison; Paolo Bonetti; Li Guo; Vy Luong; Alan Garfinkel; Saad Younis; Maria Francesca Cordeiro
Journal:  Expert Rev Mol Diagn       Date:  2020-12-28       Impact factor: 5.225

Review 8.  Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion.

Authors:  Konstantinos Balaskas; Winfried M Amoaku; Tomas Cudrnak; Louise M Downey; Markus Groppe; Sajjad Mahmood; Hemal Mehta; Quresh Mohamed; Bushra Mushtaq; Philip Severn; Athanasios Vardarinos; Yit C Yang
Journal:  Ophthalmol Ther       Date:  2021-04-10

9.  Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.

Authors:  Emily Li; Simone Donati; Kristina B Lindsley; Magdalena G Krzystolik; Gianni Virgili
Journal:  Cochrane Database Syst Rev       Date:  2020-05-05

10.  Validation and Clinical Applicability of Whole-Volume Automated Segmentation of Optical Coherence Tomography in Retinal Disease Using Deep Learning.

Authors:  Marc Wilson; Reena Chopra; Megan Z Wilson; Charlotte Cooper; Patricia MacWilliams; Yun Liu; Ellery Wulczyn; Daniela Florea; Cían O Hughes; Alan Karthikesalingam; Hagar Khalid; Sandra Vermeirsch; Luke Nicholson; Pearse A Keane; Konstantinos Balaskas; Christopher J Kelly
Journal:  JAMA Ophthalmol       Date:  2021-09-01       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.